secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001628280-24-035194
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M
-----------------------------------------------------------------------------

- Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.
- Net loss $80.3M ($0.82/ADS loss), improved from $120.9M loss ($1.25/ADS) in Q2 2023.
- Raises full-year VYVGART revenue guidance to exceed $80.0M; cash position $730.0M as of June 30.
- Three NMPA product approvals: XACDURO (HABP/VABP), efgartigimod SC (gMG), AUGTYRO (ROS1+ NSCLC).
- Expanded global oncology pipeline with next-gen ROR1 ADC (ZL-6301) via MabCare partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024035194/0001628280-24-035194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828024035194/zlab-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer